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Introduction: Radiofrequency catheter ablation (RFCA) that targets pulmonary veins (PV)
is an established treatment for paroxysmal atrial ﬁbrillation (PAF). Recent studies have
demonstrated that RFCA can eliminate PAF in over 90% of patients. However, the
eﬀectiveness for persistent or permanent AF has not been clariﬁed.
Methods and Results: 27 patients (29%) had persistent or permanent AF. RFCA including
PV antrum isolation (PVAI) was performed using a circular mapping catheter in the patients
with persistent or permanent AF. Four patients (15%) underwent only PVAI. Thirteen patients
(48%) underwent PVAI and left atrium roof and/or mitral isthmus linear ablation. Ten
patients (37%) underwent PVAI and RFCA to an area with complex fractionated atrial
electrograms. All patients were observed for over a year. After repeat ablation at mean follow-
up of 16 5 months, 23 patients (85%) had normal sinus rhythm and were free of
symptomatic AF or atrial ﬂutter. Three patients required antiarrhythmic drugs to maintain
sinus rhythm during follow-up period. One patient had a transient phrenic nerve injury. Two
patients were documented with sustained atrial tachycardia (AT). Mapping in 2 patients
showed a macro reentry AT due to gaps in the ablation lines and further ablation was needed.
No other complications including PV stenosis occurred.
Conclusions: The present study demonstrated that RFCA is an eﬀective and feasible
treatment for persistent or permanent AF.
(J Arrhythmia 2007; 23: 229–235)
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Introduction
Atrial ﬁbrillation (AF) is the most common
sustained cardiac arrhythmia and is associated with
signiﬁcant morbidity and mortality in humans.1,2)
Most AF is initiated by premature beats from the
oriﬁces of the pulmonary veins (PV) or from the
myocardial sleeves inside the PV.3) Therefore,
radiofrequency catheter ablation (RFCA) that targets
PV can be an eﬀective treatment for AF. Current
RFCA strategies for AF consist of a standardized
approach for PV isolation and/or encirclement with
or without additional RFCA lines.3–9)
However, because the pathogenesis of AF is
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multifactorial,10) a standardized RFCA approach
may not be equally eﬀective or eﬃcient in all
patients with AF. Recently, it has been suggested
that AF also can be eliminated by targeting complex
fractionated atrial electrograms (CFAEs) character-
ized by a short cycle length, fractionation, and/or
continuous electric activity.11) In the present study,
we evaluated whether RFCA procedures are also
eﬀective for persistent or permanent AF.
Methods
Study Subjects
The study population consisted of 27 consecutive
patients (mean age, 61 12 years) with symptomat-
ic drug-refractory persistent or permanent AF who
were referred for an electrophysiological study and
RFCA. Patients who were recruited at our institution
from January 2005 to January 2006, and had
undergone a prior procedure for AF were excluded
from this study. All patients were observed for over
a year. AF was considered persistent when it was
present for more than 7 days and when cardioversion
was required to restore sinus rhythm. AF was
considered permanent when it was present for more
than 30 days and when cardioversion failed to
convert sinus rhythm. In the present study, persistent
and permanent AF were considered as chronic AF
(CAF). The 27 CAF patients included 15 patients
with persistent AF and 12 patients with permanent
AF. Of the 27 patients, 2 patients had coronary artery
disease, 3 had cardiomyopathy, and the remaining
22 patients had no structural heart disease. Echocar-
diography demonstrated a mean left ventricular
ejection fraction of 64%  12%, and mean left
atrial dimension of 39 6mm.
Electrophysiological Study
Electrophysiological study and RFCA procedure
was performed in the fasting state after written
informed consent was obtained. Patients received an
oral anticoagulant for at least 1 month before RFCA.
Antiarrhythmic drugs were discontinued at ﬁve half-
lives before ablation. Two 6-French quadripolar
electrode catheters (Daig, USA) were placed in the
right atrial (RA) appendage and close to the His
bundle area. One 6-French decapolar electrode
catheter (Japan Lifeline) was placed in the coronary
sinus (CS) through the right internal cervical vein.
After biatrial angiography, transseptal approach was
utilized with three 8.5-French long sheaths (Daig)
for both the puncture and to introduce catheters for
mapping and ablation. After the transseptal puncture,
systemic anticoagulation was achieved with intra-
venous heparin (100 U/Kg) to maintain an activated
clotting time of 250–300 seconds. The presence of
PV potentials was examined with a 20-electrode ring
catheter (Lasso, Biosense-Webster, USA) positioned
at the PV-LA junction.
RFCA
All patients with CAF underwent PVAI. PVAI
was performed as previously described12) in detail
using double Lasso technique. Complete isolation of
PV was considered to be bidirectional conduction
block between the PV and LA based on both the
inability to capture the LA during distal PV pacing
and abolition of distal PV potentials. The ﬁrst 4
patients underwent PVAI only. LA roof and/or
mitral isthmus linear ablation were added for the
other patients. RFCA to mitral isthmus was per-
formed with a line between inferior portion of left
inferior PV and lateral mitral valve annulus in the
right anterior oblique position. RF energy was
delivered with a temperature-controlled, 8-mm
and/or 4-mm tip, deﬂectable quadripolar catheter
(EP technologies, Navistar, Ablaze), at a target
temperature of 50 C and a maximum output of 30W
for 30–60 s at each ostial site. If the activation
sequence around the PV-LA junction was changed,
the bipole that showed the new earliest atrial
potential was targeted. Three-dimensional images
of the PVs were reconstructed by contrast-enhanced
multi-detector computed tomography (MDCT) be-
fore RFCA. When AF was still present or inducible
after complete PV isolation, RFCA of area with
CFAEs was performed. A 3-dimensional depiction
of the LA and PVs with an electroanatomical
mapping system (CARTO, Biosense-Webster) was
created before RFCA to detect the area with CFAEs.
CFAE sites were tagged. At tagged sites, RF energy
was applied until the maximum local electrogram
amplitude decreased by >50% or to <0:1mV. If
AF converted to atrial tachycardia during RFCA
to CFAE sites (Figure 1), AF was considered as
eliminated and we converted them to sinus rhythm
by external cardioversion. The endpoint of RFCA
was the complete isolation of PV veriﬁed by
circumferential PV mapping and no reinducibility
of AF. According to the study protocol, reinduction
was attempted by pacing from high RA at the
shortest cycle length with isoproterenol infusion,
resulting in 1:1 atrial capture. AF was considered
inducible if it lasted > 5 minutes, and further
mapping and RFCA were performed. If AF was still
inducible and maintained after achievement of the
procedural endpoint, transthoracic cardioversion was
performed to restore sinus rhythm.
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Figure 1 Ablation of CFAEs.
Case 1 65M Permanent AF. (A) before RFCA. (B) after RFCA. (C) termination.
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Follow-up
Warfarin was administered and continued for at
least 3 months with an international normalized ratio
level of approximately 2.0. Post-RFCA follow-up
exams were performed at the same institution,
initially at 1 week and subsequently at 1-month
intervals. Clinical examination, 12-lead ECG, and
24-h Holter recordings were made every 3 months
and when symptoms suggested recurrence of an
arrhythmia. MDCT was performed at 6 months and
12 months after RFCA to assess stenosis of the PVs.
A change in the PV diameter as measured by MDCT
between before and 12 months after RFCA that
showed a decrease in PV diameter of more than 50%
was considered signiﬁcant. In addition, echocardiog-
raphy was performed to evaluate cardiac function
after a period of sinus rhythm maintenance for same
patients. Because early recurrence of AF may be
transient,13) a blanking period of 8 weeks was used.
Successful clinical outcome was deﬁned as the
absence of recurrent AF or atrial ﬂutter (starting at
8 weeks of follow-up) without the use of antiar-
rhythmic drugs. The mean duration of follow-up was
16 5 months after the last ablation procedure.
Survival curves were estimated by the log–rank test.
P < 0:05 was considered to indicate statistical
signiﬁcance.
Results
Lasso Mapping Catheter-Guided PV Isolation
PV isolation was performed in all 27 patients (107
targeted PVs mean 3.96 per patient), and all PVs
were isolated successfully. Bidirectional conduction
block between the PV and LA was conﬁrmed by PV-
LA dissociation in all PVs.
Clinical Outcome
The mean duration of follow-up was 16 5
months (> 6 months) after the last RFCA procedure.
Of 27 patients with CAF who underwent RFCA,
PVAI alone was performed on 4 patients (15%).
Three of these 4 patients (75%) were free from AF
without antiarrhythmic drug therapy. The mean total
procedure time for PVAI was 143 33min and the
mean ﬂuoroscopy time was 56 12min. Thirteen
patients (48%) were treated with PVAI and LA roof
and/or mitral isthmus linear ablation. Ten of 13
patients (77%) were free from AF without antiar-
rhythmic drug therapy, while the remaining 1 patient
required antiarrhythmic drug treatment to maintain
sinus rhythm. PVAI and LA roof and/or mitral
isthmus linear ablation required a mean total
procedure time of 204 75min and a mean ﬂuoro-
scopy time of 78 32min. In 10 patients (37%) who
underwent PVAI and RFCA to the area with CFAEs,
AF was eliminated in 9 patients (90%). Seven of
10 patients (70%) were free from AF without
antiarrhythmic drug therapy, while the remaining 2
patients required antiarrhythmic drug treatment to
maintain sinus rhythm during the follow-up period
(Figure 2). PVAI and RFCA to the area with CFAEs
required a mean total procedure time of 245 86
min and a mean ﬂuoroscopy time of 90 39min.
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Figure 2 Success rate of each methodology.
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There was no signiﬁcant diﬀerence in the recurrence
rate between the three groups of each methodology
(Figure 3). Ablation to CFAEs eliminated AF at LA
septum, crista terminalis, LA roof, RA appendage,
and mitral isthmus.
After the initial RFCA procedure, a repeat RFCA
was performed in 15 of the 27 patients (55%; mean
sessions, 1.67 times) because of the recurrence of AF
or atrial ﬂutter. In summary, 23 of the 27 patients
(85%) had normal sinus rhythm and were free of
symptomatic AF or atrial ﬂutter. Three patients
required antiarrhythmic drugs to maintain sinus
rhythm during follow-up period. There was no
diﬀerence in the recurrence rate between persistent
AF and permanent AF (Figure 3). The mean total
procedure time was 198 71 minutes and the mean
total ﬂuoroscopy time was 79 34 minutes.
Four patients underwent echocardiography to
evaluate cardiac function after a period of sinus
rhythm maintenance. Cardiac function improved in
all patients (Table 1).
Complications
One patient who underwent ablation at CFAEs
developed transient phrenic nerve injury. Two
patients were documented with sustained AT. Map-
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Figure 3 Kaplan-Meier curves for
AF free ratio.
(A) Outcomes of each methodology
without antiarrhythmic drugs. (B) Out-
comes of permanent and persistent AF.
PVAI: PV antrum isolation, SR: sinus
rhythm, AF: atrial ﬁbrillation, CFAEs:
complex fractionated atrial electro-
grams
Table 1 Change of echocardiography before and after ablation.
case age gender LAD mm pre/post EF (%) pre/post follow up period
1 44 M 49/38 61/70 4 months
2 61 M 52/46 67/70 8 months
3 65 M 39/34 72/77 4 months
4 70 M 50/38 36/49 12 months
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ping in 2 patients showed a macro reentry AT due to
gaps in the ablation lines and further ablation was
needed. No PV stenoses were detected by MDCT
after the RFCA procedure.
Discussion
Main Findings
The present study indicated that RFCA, including
PVAI, of all PVs was eﬀective in maintaining sinus
rhythm in patients with drug-resistant persistent or
permanent AF. At mean follow-up of 16 5 months,
23 patients (85%) had normal sinus rhythm and were
free from symptomatic AF or atrial ﬂutter. Three
patients required antiarrhythmic drugs to maintain
sinus rhythm during the follow-up period. Conver-
sion to sinus rhythm, and freedom from antiarrhyth-
mic drugs signiﬁcantly improved cardiac function.
Transient phrenic nerve injury occurred in 1 patient
after the RFCA procedure, but there were no other
complications including PV stenosis during follow-
up period. Thus, RFCA is an eﬀective and safe
treatment for persistent or permanent AF.
RFCA Strategy
In patients with CAF, the PVs are also the
dominant trigger for initiating AF after electrical
cardioversion.14) PVs may have an important role not
only in the onset, but also the maintenance of AF.15)
However, they do not always lead to AF. RFCA
technique that targets only the PV ostium have had
modest eﬃcacy in CAF.3,4,16) Consistent with the
multifactorial nature of AF,10) autonomic innervation
of the LA, non-PV arrhythmogenicity, multiple
reentrant wavelets, and anisotropic reentry leading
to rotors were all implicated in the genesis of AF.
Therefore, elimination of only PV input may not be
suﬃcient in all patients with CAF. Although the
signiﬁcance of CFAEs are still unknown, it may be
associated with the mechanism of AF maintenance.
Animal studies demonstrated that rotors drive AF in
the LA.17,18) The central core of these rotors may
have high-frequency electric activity, whereas the
periphery of the rotors may display complex electro-
grams because of wave break and ﬁbrillatory con-
duction.19–21) CFAEs may also indicate the sites of
wave collision, slow conduction, or pivot points
for reentrant circuits,22) and may facilitate multiple
wavelet reentry. It is also possible that CFAEs reﬂect
underlying ganglionated plexi, providing another
potential reason for these RFCA sites.23) We per-
formed RFCA of area with CFAEs for the patients
who did not respond to the electrical PV disconnec-
tion from the atrium. RFCA of area with CFAEs are
eﬀective for a greater part of these patients. It is
suggested that RFCA to CFAEs could be the next
option for the patients with CAF who did not
respond to PVAI. In the present study, RFCA to
CFAEs sites led to restoration to sinus rhythm
and improvement of cardiac function. It has been
demonstrated that restoration and maintenance of
sinus rhythm by catheter ablation in patients with
CAF without drugs improved cardiac function.24)
Thus, the adaptation of RFCA can expand to
persistent or permanent AF. Further clinical data
will justify the indication of invasive RFCA for
persistent or permanent AF.
Study limitation
There were a few limitations in this study. First,
although the study reached some conclusions, only a
relatively small number of patients were evaluated.
Second, the clinical outcome of RFCA procedure
to CAF was judged based on the symptoms of the
patients, serial ECG recordings over a limited time,
and 24-hour Holter data. Thus, the patients with
asymptomatic AF recurrence might have been
underestimated. Further studies are needed to answer
to these questions.
Conclusions
The present study demonstrated that RFCA is an
eﬀective and feasible treatment for persistent or
permanent AF. RFCA to CFAEs could be the next
option for the patients with CAF who did not
respond to PVAI, resulting in improvement of
cardiac function. These results suggest that RFCA
is highly eﬀective in patients with CAF.
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